We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fibroblast Growth Factor 23 Associated with Diabetic CV Risks

By LabMedica International staff writers
Posted on 26 Oct 2019
Print article
Image: The Lumipulse G600 II is a fully automated benchtop chemiluminescent enzyme immunoassay analyzer (Photo courtesy of Fujirebio Europe).
Image: The Lumipulse G600 II is a fully automated benchtop chemiluminescent enzyme immunoassay analyzer (Photo courtesy of Fujirebio Europe).
There is an association between higher levels of fibroblast growth factor 23 (FGF23), and greater cardiovascular and mortality risks for adults with type 2 diabetes and normal or mildly impaired kidney function

Fibroblast growth factor 23 is a protein that in humans is encoded by the FGF23 gene. FGF23 is a member of the fibroblast growth factor (FGF) family, which is responsible for phosphate (phosphate homeostasis) and vitamin D metabolism.

Medical scientists at the University of Groningen (Groningen, the Netherlands) and their colleagues assessed FGF23 levels in 310 adults with type 2 diabetes and an eGFR of 60 mL/min/1.73 m2 or more (mean age, 61.5 years; 42.1% women) from the Diabetes and Lifestyle Cohort Twente (DIALECT) study. In addition, the team used hospital surveillance data to evaluate all-cause mortality and major adverse cardiovascular (CV) events across a median of 5.8 years of follow-up.

Plasma C-terminal FGF23 levels were determined by sandwich ELISA, with intra-assay and interassay coefficients of variation of 0.5% and 0.16% respectively. Phosphate, albumin and creatinine were determined by a colorimetric method with COBAS 6000. Parathyroid hormone (PTH) was determined by the electrochemiluminescence sandwich immunoassay method using COBAS 6000. 25-hydroxy vitamin D was determined by electrochemiluminescence sandwich immunoassay with Lumipulse. HbA1c was measured by the Roche Tina‐quant 3rd generation immunoturbidimetric method.

The team reported that compared with 110 participants with an eGFR of less than 60 mL/min/1.73 m2 from the original DIALECT cohort, those included in the analysis had lower FGF23 levels (84.2 relative units/mL versus 146.5 relative units/mL). There is an association between higher levels of FGF23, and greater cardiovascular and mortality risks for adults with type 2 diabetes and normal or mildly impaired kidney function. They also reported 28 deaths and 47 major adverse CV events among participants. In fully adjusted models, they found all-cause mortality risk was 2.74 times greater and major adverse CV event risk was 1.56 times greater with each doubling of FGF23. Additionally, in fully adjusted models, the researchers found all-cause mortality risk was 3.33 times greater with each doubling of FGF23 for those with an eGFR of at least 90 mL/min/1.73 m2, although major adverse CV event risk was not changed by a statistically significant margin.

Martin H. de Borst, MD, PhD, a consultant nephrologist and a co-author of the study said, “So far, most studies had focused on the role of FGF23 in patients with reduced kidney function. Now, we have shown that FGF23 levels are also linked with adverse outcomes in patients with type 2 diabetes and normal or mildly impaired kidney function. This hormone may therefore be relevant to a larger group of individuals than previously thought.”

The authors concluded that in patients with type 2 diabetes and normal or mildly impaired kidney function, FGF23 is associated with an increased risk of cardiovascular events and mortality. The study was published in the October 2019 issue of the journal Diabetes Care.

Related Links:
University of Groningen

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.